You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Investigational Drug Information for Merestinib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Merestinib?

Merestinib is an investigational drug.

There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2016.

The most common disease conditions in clinical trials are Neoplasms, Neoplasm Metastasis, and Microsatellite Instability. The leading clinical trial sponsors are Eli Lilly and Company, University of Utah, and Dana-Farber Cancer Institute.

There are nine US patents protecting this investigational drug and two hundred and twenty international patents.

Recent Clinical Trials for Merestinib
TitleSponsorPhase
Merestinib on Bone Metastases in Subjects With Breast CancerEli Lilly and CompanyPhase 1
Merestinib on Bone Metastases in Subjects With Breast CancerUniversity of UtahPhase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaEli Lilly and CompanyPhase 1

See all Merestinib clinical trials

Clinical Trial Summary for Merestinib

Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib

See all Merestinib clinical trials

US Patents for Merestinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Merestinib ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Merestinib ⤷  Sign Up Methods of treating a neuroendocrine tumor SCRIPPS HEALTH (San Diego, CA) ⤷  Sign Up
Merestinib ⤷  Sign Up Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Merestinib ⤷  Sign Up Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Sign Up
Merestinib ⤷  Sign Up Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) ⤷  Sign Up
Merestinib ⤷  Sign Up Macrocylic compounds as ROS1 kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Merestinib

Drugname Country Document Number Estimated Expiration Related US Patent
Merestinib Australia AU2017261372 2036-05-05 ⤷  Sign Up
Merestinib Canada CA3023278 2036-05-05 ⤷  Sign Up
Merestinib China CN107847398 2036-05-05 ⤷  Sign Up
Merestinib European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Merestinib European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
Merestinib Hong Kong HK1249728 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.